Access the full text.
Sign up today, get DeepDyve free for 14 days.
C.J.A. Moorsel, H. Pinedo, G. Veerman, A. Bergman, C. Kuiper, J. Vermorken, Wjf Vijgh, G. Peters (1999)
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell linesBritish Journal of Cancer, 80
J. Pfisterer, I. Vergote, A. Bois, E. Eisenhauer (2004)
Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancerInternational Journal of Gynecologic Cancer, 15
M. Bookman (2004)
Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinicInternational Journal of Gynecologic Cancer, 15
Emilio Bajetta, S. Stani, D. Candis, Nadia Zaffaroni, N. Zilembo, Diego Cortinovis, S. Aglione, Luigi Mariani, B. Formisano, P. Bidoli (2003)
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 14 2
V.W.T. Ruiz van Haperen, G. Veerman, S. Eriksson (1994)
Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780Cancer Res, 54
B.J.M. Braakhuis, V.W.T. Ruiz van Haperen, E. Boven (1995)
Schedule-dependent antitumor effect of gemcitabine in in vivo model systemsSemin Oncol, 22
G.J. Peters, V.W.T. Ruiz van Haperen, A.M. Bergman (1996)
Preclinical combination therapy with gemcitabine and mechanisms of resistanceSemin Oncol, 10
A. Bois, H. Lück, J. Pfisterer, W. Schroeder, J.-U. Blohmer, Rainer Kimmig, V. Moebus, J. Quaas (2001)
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.Annals of oncology : official journal of the European Society for Medical Oncology, 12 8
J. Sehouli (2005)
Review of gemcitabine‐based combinations for platinum‐resistant ovarian cancerInternational Journal of Gynecological Cancer, 15
D. Armstrong (2002)
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.The oncologist, 7 Suppl 5
M. Edelman, H. Quam, B. Mullins (2001)
Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell linesCancer Chemotherapy and Pharmacology, 48
M.R. Green (1996)
Gemcitabine safety overviewSemin Oncol, 23
Jennifer Williams, P. Lucas, K. Griffith, Milheon Choi, Sarah Fogoros, Yuan-Yuan Hu, J. Liu (2005)
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.Gynecologic oncology, 96 2
AM Bergman, H. Pinedo, I. Talianidis, G. Veerman, Wjp Loves, CL Wilt, GJ Peters (2003)
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell linesBritish Journal of Cancer, 88
C. Dunton (2002)
Management of treatment-related toxicity in advanced ovarian cancer.The oncologist, 7 Suppl 5
V. Haperen, G. Veerman, E. Boven, P. Noordhuis, J. Vermorken, G. Peters (1994)
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.Biochemical pharmacology, 48 7
R. Grunewald, J. Abbruzzese, P. Tarassoff, W. Plunkett (2004)
Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabineCancer Chemotherapy and Pharmacology, 27
T. Bauknecht, T. Einzmann, T. Brandstetter (1997)
The cell cycle arrest and apoptosis in ovarian cancer cells exposed to cisplatin and gemcitabine are p53 dependent, in cells exposed to taxol p53 independent [abstract]Gynecol Oncol, 64
M. Kose, J. Šufliarský, S. Bešlija, P. Saip, G. Tulunay, K. Krejcy, T. Minárik, E. Fitzthum, A. Hayden, A. Melemed (2005)
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.Gynecologic oncology, 96 2
A.M. Bergman, V.W.T. Ruiz van Haperen, G. Veerman (1996)
Synergistic interaction between cisplatin and gemcitabine in vitroClin Cancer Res, 2
C. Papadimitriou, G. Fountzilas, G. Aravantinos, C. Kalofonos, L. Moulopoulos, E. Briassoulis, D. Gika, M. Dimopoulos (2004)
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.Gynecologic oncology, 92 1
T. Herzog (2004)
Recurrent Ovarian CancerClinical Cancer Research, 10
A.A. Alvarez, D.L. Clarke-Pearson (2003)
Platinum-resistant and refractory ovarian cancer: second-line treatment optionsAm J Cancer, 2
N. Cloven, A. Kyshtoobayeva, R. Burger, I. Yu, J. Fruehauf (2004)
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.Gynecologic oncology, 92 1
L. Cartee, G. Kucera (1998)
Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cellsCancer Chemotherapy and Pharmacology, 41
R.D. Alvarez, M. Orlando, R.S. Manuel (2004)
Three-arm phase I study of fixed-dose rate (FDR) gemcitabine (Gem) + carboplatin (Cb) in relapsed, platinum-sensitive (Pt-S) ovarian cancer (OC) patients (pts): results of the first cohort [abstract no. 482P]Ann Oncol, 15
P. Cappella, D. Tomasoni, M. Faretta, M. Lupi, Francesco Montalenti, Federica Viale, Fabio Banzato, M. D’Incalci, P. Ubezio (2001)
Cell cycle effects of gemcitabineInternational Journal of Cancer, 93
E. Eisenhauer, J. Vermorken, M. Glabbeke (1997)
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].Annals of oncology : official journal of the European Society for Medical Oncology, 8 10
Judith Smith, Jubilee Brown, M. Martin, L. Ramondetta, J. Wolf (2004)
An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.Gynecologic oncology, 92 1
J. Carmichael, S. Allerheiligen, J. Walling (1996)
A phase I study of gemcitabine and carboplatin in non-small cell lung cancerSemin Oncol, 10
T.J. Herzog (2004)
Recurrent ovarian cancer: how important is it to treat to disease progression?Clin Cancer Res, 10
A. Jemal, R. Tiwari, Taylor Murray, Asma Ghafoor, A. Samuels, Elizabeth Ward, E. Feuer, M. Thun (2004)
Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 54
A. Alvarez, D. Clarke‐Pearson (2003)
Platinum-Resistant and Refractory Ovarian CancerAmerican Journal of Cancer, 2
V. Haperen, G. Veerman, P. Noordhuis, J. Vermorken, G. Peters (1991)
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).Advances in experimental medicine and biology, 309A
E. Boven, H. Schipper, C. Erkelens, S. Hatty, H. Pinedo (1993)
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.British Journal of Cancer, 68
J. Abbruzzese, R. Grunewald, E. Weeks, Diane Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, M. Raber (1991)
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 3
Mazin Moufarij, D. Phillips, C. Cullinane (2003)
Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.Molecular pharmacology, 63 4
André Bergman, V. Haperen, G. Veerman, C. Kuiper, Godefridus Peters (1994)
Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.Advances in experimental medicine and biology, 370
▴ Gemcitabine has well established antitumor activity against a variety of solid tumors, including ovarian cancer, and hematologic malignancies. It has recently been approved in several European countries for use with carboplatin for the treatment of advanced ovarian cancer in patients with recurrent disease ≥6 months after platinum-based, first-line therapy.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.